drugset / Trial / NCT01225640
PNU-100480 In Newly Diagnosed, Drug Sensitive Patients With Pulmonary TB; Early Bactericidal Activity; Whole Blood Assay
RandomizedParallel-groupOpen-labelTreatment
Summary
PNU-100480 is being developed for the treatment of both drug resistant and sensitive tuberculosis. This is an efficacy and safety study to characterize the effect of PNU-100480 when given for 14 days to treatment-naive patients with drug-sensitive pulmonary tuberculosis.
Timeline
- Start
- 2011-08
- Primary completion
- 2011-12
- Completion
- 2011-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Ethambutol | Small molecule | 275 mg | — |
| Comparator | Isoniazid | Small molecule | 75 mg | — |
| Comparator | Pyrazinamide | Small molecule | 400 mg | — |
| Comparator | Rifampin | Small molecule | 150 mg | — |
| Subject | Sutezolid | Small molecule | 600 mg | — |
| Subject | Sutezolid | Small molecule | 1200 mg | — |